HAOHAI BIOTEC (06826) announced its interim results, with a net profit attributable to the parent company of approximately 113 million yuan, a year-on-year decrease of 46.64%.

HAOHAI BIOTEC (06826) announced its mid-term results for 2026, with operating revenue of approximately 1.166 billion yuan, a year-on-year decrease of about 9.81%; net profit attributable to shareholders of the listed company was approximately 113 million yuan, a year-on-year decrease of 46.64%; earnings per share were 0.49 yuan, and the interim dividend was 0.25 yuan per share (before tax). The announcement stated that the decline in net profit was mainly due to the decrease in sales revenue, particularly from hyaluronic acid products, which resulted in reduced gross profit. Additionally, the medical device workshop and comprehensive supporting facilities of Shanghai Haohai Biological Technology's international pharmaceutical research and development and industrialization project were transferred from construction in progress to fixed assets in February 2026, resulting in an increase in depreciation and amortization expenses exceeding 21 million yuan.